Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus INDICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus INDICLOR.
ANAPROX DS vs INDICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
INDICLOR is not a recognized drug; no standard dosing available.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Category C
Category C
NSAID
NSAID